(FTV) Fortive - Ratings and Ratios
Sensors, Instruments, Sterilizers, Tracking, Biomedical
Dividends
| Dividend Yield | 0.61% |
| Yield on Cost 5y | 0.65% |
| Yield CAGR 5y | 3.39% |
| Payout Consistency | 97.5% |
| Payout Ratio | 9.4% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 20.8% |
| Value at Risk 5%th | 32.2% |
| Relative Tail Risk | -5.99% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.40 |
| Alpha | -22.99 |
| CAGR/Max DD | 0.08 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.398 |
| Beta | 0.953 |
| Beta Downside | 1.085 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.01% |
| Mean DD | 11.12% |
| Median DD | 10.64% |
Description: FTV Fortive October 30, 2025
Fortive Corp (NYSE:FTV) designs, develops, manufactures, and markets a broad portfolio of products, software, and services across the United States, China, and other international markets. The company is organized into two operating segments: Intelligent Operating Solutions (IOS) and Advanced Healthcare Solutions (AHS). IOS delivers instrumentation, test-and-measurement equipment, lifecycle-management software, and connected-worker safety tools for industries ranging from manufacturing to utilities, under brands such as FLUKE, GORDIAN, and PRUFTECHNIK. AHS focuses on critical workflow solutions for the healthcare sector, including instrument sterilization, cell-therapy equipment, radiation detection, and clinical productivity software, marketed under names like STERRAD, LANDAUER, and FLUKE BIOMEDICAL.
Key performance indicators from the most recent fiscal year (FY 2023) show total revenue of approximately $5.5 billion, with the AHS segment growing ~8 % YoY, outpacing the IOS segment’s modest 3 % increase. Operating margin hovered around 12 %, reflecting continued cost-discipline despite inflationary pressure on component costs. The industrial automation trend-driven by rising demand for digital twins and predictive maintenance-remains a primary growth catalyst for IOS, while an aging global population and expanding outpatient care settings underpin AHS demand for sterilization and workflow solutions.
Given Fortive’s diversified end-markets and steady cash-flow generation, analysts often monitor its free-cash-flow conversion (historically > 80 %) and capital-allocation strategy, especially the balance between dividend payouts and share-repurchase programs. For a deeper dive into Fortive’s valuation metrics and comparable peers, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (602.3m TTM) > 0 and > 6% of Revenue (6% = 338.4m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 1.35pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -13.08% (prev 8.63%; Δ -21.71pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 1.19b > Net Income 602.3m (YES >=105%, WARN >=100%) |
| Net Debt (2.88b) to EBITDA (1.39b) ratio: 2.07 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (333.4m) change vs 12m ago -5.36% (target <= -2.0% for YES) |
| Gross Margin 60.33% (prev 59.74%; Δ 0.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 38.45% (prev 35.50%; Δ 2.95pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.55 (EBITDA TTM 1.39b / Interest Expense TTM 122.6m) >= 6 (WARN >= 3) |
Altman Z'' 2.49
| (A) -0.06 = (Total Current Assets 1.73b - Total Current Liabilities 2.47b) / Total Assets 11.89b |
| (B) 0.44 = Retained Earnings (Balance) 5.26b / Total Assets 11.89b |
| (C) 0.06 = EBIT TTM 925.7m / Avg Total Assets 14.67b |
| (D) 0.99 = Book Value of Equity 5.30b / Total Liabilities 5.38b |
| Total Rating: 2.49 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 54.22
| 1. Piotroski 8.50pt |
| 2. FCF Yield 5.25% |
| 3. FCF Margin 19.18% |
| 4. Debt/Equity 0.51 |
| 5. Debt/Ebitda 2.07 |
| 6. ROIC - WACC (= -5.24)% |
| 7. RoE 6.46% |
| 8. Rev. Trend -11.92% |
| 9. EPS Trend -40.50% |
What is the price of FTV shares?
Over the past week, the price has changed by +1.00%, over one month by +4.68%, over three months by +12.76% and over the past year by -8.69%.
Is FTV a buy, sell or hold?
- Strong Buy: 6
- Buy: 5
- Hold: 9
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the FTV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 57.2 | 6.6% |
| Analysts Target Price | 57.2 | 6.6% |
| ValueRay Target Price | 53.6 | -0.1% |
FTV Fundamental Data Overview November 26, 2025
P/E Trailing = 20.6535
P/E Forward = 18.9036
P/S = 2.8352
P/B = 2.5618
P/EG = 1.2896
Beta = 1.05
Revenue TTM = 5.64b USD
EBIT TTM = 925.7m USD
EBITDA TTM = 1.39b USD
Long Term Debt = 2.12b USD (from longTermDebt, last quarter)
Short Term Debt = 1.19b USD (from shortTermDebt, last quarter)
Debt = 3.31b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.88b USD (from netDebt column, last quarter)
Enterprise Value = 20.62b USD (17.75b + Debt 3.31b - CCE 430.8m)
Interest Coverage Ratio = 7.55 (Ebit TTM 925.7m / Interest Expense TTM 122.6m)
FCF Yield = 5.25% (FCF TTM 1.08b / Enterprise Value 20.62b)
FCF Margin = 19.18% (FCF TTM 1.08b / Revenue TTM 5.64b)
Net Margin = 10.68% (Net Income TTM 602.3m / Revenue TTM 5.64b)
Gross Margin = 60.33% ((Revenue TTM 5.64b - Cost of Revenue TTM 2.24b) / Revenue TTM)
Gross Margin QoQ = 63.21% (prev 58.97%)
Tobins Q-Ratio = 1.74 (Enterprise Value 20.62b / Total Assets 11.89b)
Interest Expense / Debt = 0.77% (Interest Expense 25.4m / Debt 3.31b)
Taxrate = 59.26% (80.0m / 135.0m)
NOPAT = 377.1m (EBIT 925.7m * (1 - 59.26%))
Current Ratio = 0.70 (Total Current Assets 1.73b / Total Current Liabilities 2.47b)
Debt / Equity = 0.51 (Debt 3.31b / totalStockholderEquity, last quarter 6.50b)
Debt / EBITDA = 2.07 (Net Debt 2.88b / EBITDA 1.39b)
Debt / FCF = 2.66 (Net Debt 2.88b / FCF TTM 1.08b)
Total Stockholder Equity = 9.33b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.07% (Net Income 602.3m / Total Assets 11.89b)
RoE = 6.46% (Net Income TTM 602.3m / Total Stockholder Equity 9.33b)
RoCE = 8.09% (EBIT 925.7m / Capital Employed (Equity 9.33b + L.T.Debt 2.12b))
RoIC = 2.85% (NOPAT 377.1m / Invested Capital 13.25b)
WACC = 8.08% (E(17.75b)/V(21.06b) * Re(9.53%) + D(3.31b)/V(21.06b) * Rd(0.77%) * (1-Tc(0.59)))
Discount Rate = 9.53% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.02%
[DCF Debug] Terminal Value 74.62% ; FCFE base≈1.19b ; Y1≈1.31b ; Y5≈1.69b
Fair Price DCF = 71.16 (DCF Value 22.60b / Shares Outstanding 317.6m; 5y FCF grow 11.56% → 3.0% )
EPS Correlation: -40.50 | EPS CAGR: -3.92% | SUE: 1.22 | # QB: 1
Revenue Correlation: -11.92 | Revenue CAGR: -7.48% | SUE: 0.11 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.63 | Chg30d=+0.011 | Revisions Net=+2 | Analysts=8
EPS next Year (2026-12-31): EPS=2.85 | Chg30d=+0.095 | Revisions Net=+11 | Growth EPS=+7.8% | Growth Revenue=+2.9%
Additional Sources for FTV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle